Meeting clinical needs in biomarker discovery and characterisation

Thermo Fisher Scientific has announced collaborations of the Thermo Fisher Precision Medicine Science Center with AstraZeneca and the University of Nebraska Medical Center in development of innovative solutions in clinical biomarker discovery.

The new alliances strengthen the Precision Medicine Science Center (PMSC) mission of creating standardised workflows with pharmaceutical and academic partners to streamline the transition from biomarker research to clinical implementation, creating new opportunities for precision medicine.


Ongoing and planned studies with both AstraZeneca and the University of Nebraska Medical Center will utilise standardised plasma protein profiling workflows, including Thermo Fisher’s newly developed ultra-high throughput plasma protein profiling (uHTPPP) workflow, for biomarker discovery, for a range of conditions. The standardised workflows consist of automated sample preparation for untargeted and targeted methods in combination with the Thermo Scientific Orbitrap Exploris 480 (pictured) and Thermo Scientific Orbitrap Exploris 240 spectrometers.
 

www.thermofisher.com

Upcoming Events

SHOT Report 2019: ADU highlights webinar

Online
28 January 2021

COVID-19 - The Infection that Challenged the World: Is Necessity the Mother of Invention?

Online
11-14 May 2021

Lab Innovations 2021

NEC, Birmingham
3-4 November 2021

IBMS Biomedical Science Congress 2022

International Convention Centre, Birmingham
14-17 March 2022

Upcoming Events

SHOT Report 2019: ADU highlights webinar

Online
28 January 2021

COVID-19 - The Infection that Challenged the World: Is Necessity the Mother of Invention?

Online
11-14 May 2021

Lab Innovations 2021

NEC, Birmingham
3-4 November 2021

IBMS Biomedical Science Congress 2022

International Convention Centre, Birmingham
14-17 March 2022